Skip to content
DataLookout
Menu

ENKLA-MNCT07249476

Study of NK Cells in the Monitoring of Patients With Acute Leukemia or Myelodysplasia

StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved 6 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Jun 1, 2029 to Dec 1, 2029
    • Start date: Jun 1, 2026 to Dec 1, 2026
    • Eligibility criteria expanded, about 9 words
    • Study completion pushed from Jun 1, 2030 to Dec 1, 2030
  2. Minor Study sites: 0 to 1v4
  3. Notable Start date: Feb 1, 2026 to Jun 1, 2026
    • Primary completion date: Feb 1, 2029 to Jun 1, 2029
    • Study completion date: Feb 1, 2030 to Jun 1, 2030
    v3
  4. Notable Eligibility criteria expanded, about 2 wordsv2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Define the KIR and HLA genetic markers associated with an anti-leukaemic response mediated by NK cells at different stages in the progression of Acute lymphocytic leukaemia or a myalodysplasia syndrome.
Timeframe: 12 months

Secondary (4)

Assess the functional potential of different NK cell populations at diagnosis of acute myeloid leukaemia, acute lymphoblastic leukaemia and myelodysplastic syndrome (at each possible relapse of the patient).
Assess NK cell reconstitution during transplant of hematopoietic stem cells.
Assess the impact of the hypomethylating agent AZA used to prevent relapse after allogeneic transplantation for acute myeloid leukaemia or myelodysplastic syndrome on NK cells.
Assess the impact of Donor Lymphocyte Injection used in the prevention of post-allogeneic transplant relapse on NK cells.

Arms and interventions

AZA/DLI Group

\> 20 Acute myeloid leukaemia/myelodysplastic syndrome patients receiving a matched transplant: 10 patients receiving AZA/DLI for relapse prevention. 10 patients not receiving AZA/DLI (control group). This group is monitored at diagnosis and for 12 months after transplantation.

Group without AZA/DLI

\> 20 Acute myeloid leukaemia/myelodysplastic syndrome patients receiving a haploidentical transplant: 10 patients receiving AZA/DLI for relapse prevention. 10 patients not receiving AZA/DLI (control group). This group is monitored at diagnosis and for 12 months after transplantation.

LAL (Acute lymphoblastic leukaemia)

10 Patients with a (Acute lymphoblastic leukaemia). This group is monitored at diagnosis only.

Other: Bone marrow sampling (during routine care), Blood samples (during routine care)

Sites

1 site in 1 country

  • CHU de NantesNantes, France